Abstract
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Current Pharmaceutical Biotechnology
Title: Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Volume: 7 Issue: 6
Author(s): Maurizio Zangari, Federica Cavallo and Guido Tricot
Affiliation:
Keywords: CAAX binding site, Tipifarnib, STAT3 tyrosine phosphorylation, mTOR Kinase pathway, CCI-779, haematological malignancies
Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.
Export Options
About this article
Cite this article as:
Zangari Maurizio, Cavallo Federica and Tricot Guido, Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116838
DOI https://dx.doi.org/10.2174/138920106779116838 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypocholesterolemia
Current Vascular Pharmacology Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
Current Drug Targets Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology The Enzymology of Cytosolic Pyrimidine 5’-Nucleotidases: Functional Analysis and Physiopathological Implications.
Current Medicinal Chemistry How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Leukaemia Infection Diagnosis and Intestinal Flora Disorder
Current Molecular Medicine Antibody Therapy of Acute and Chronic Leukemias
Current Pharmaceutical Biotechnology Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Combination Therapy with Arsenic Trioxide for Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design